Drugs Made In America Acquisition Ordinary Shares Total Current Liabilities

The latest total current liabilities for DMAA is $2.9M as of June 2026. That compares with $300K in the prior-year period — up 876.8% year over year. Investors often review this figure alongside Drugs Made In America Acquisition Ordinary Shares's historical trend and sector peers before judging valuation or financial health.

Over the past year, DMAA's total current liabilities moved from $300K to $2.9M — a 876.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Drugs Made In America Acquisition Ordinary Shares's operating scale or balance-sheet position.

A total current liabilities figure of $2.9M for DMAA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting DMAA's total current liabilities ($2.9M), review year-over-year change from $300K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.